WallStSmart

Cognyte Software Ltd (CGNT)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Cognyte Software Ltd generates 55% more annual revenue ($400.04M vs $258.90M). CGNT leads profitability with a -0.2% profit margin vs -15.5%. ZEPP earns a higher WallStSmart Score of 41/100 (D).

CGNT

Avoid

34

out of 100

Grade: F

Growth: 4.7Profit: 3.5Value: 6.7Quality: 6.0
Piotroski: 4/9Altman Z: 1.09

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CGNTUndervalued (+50.1%)

Margin of Safety

+50.1%

Fair Value

$14.43

Current Price

$9.33

$5.10 discount

UndervaluedFair: $14.43Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CGNT1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.189/10

Conservative balance sheet, low leverage

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

CGNT4 concerns · Avg: 2.8/10
Market CapQuality
$696.96M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
2.1%3/10

ROE of 2.1% — below average capital efficiency

Operating MarginProfitability
4.9%3/10

Operating margin of 4.9%

EPS GrowthGrowth
-74.8%2/10

Earnings declined 74.8%

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : CGNT

The strongest argument for CGNT centers on Debt/Equity. Revenue growth of 12.4% demonstrates continued momentum.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : CGNT

The primary concerns for CGNT are Market Cap, Return on Equity, Operating Margin.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

CGNT profiles as a turnaround stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor SOFTWARE - INFRASTRUCTURE industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZEPP scores higher overall (41/100 vs 34/100) and 43.0% revenue growth. CGNT offers better value entry with a 50.1% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cognyte Software Ltd

TECHNOLOGY · SOFTWARE - INFRASTRUCTURE · USA

Cognyte Software Ltd. provides security analysis software to governments and companies around the world. The company is headquartered in Herzliya, Israel.

Visit Website →

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?